Ads
related to: factor viii warnings- Dosing & Administration
Information on Dosing,
Reconstitution and Administration.
- Getting Patients Started
Find Resources & Tools To Help Your
Patients, Right From The Start.
- HCP Educational Resources
Find Materials To Help You Make
Informed Treatment Decisions.
- Costs & Coverage
Help Eligible Patients Access Copay
Savings, Product Assistance & More.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Coagulation factor VIII (Factor VIII, FVIII, also known as anti-hemophilic factor (AHF)) is an essential blood clotting protein. In humans, it is encoded by F8 gene . [ 5 ] [ 6 ] Defects in this gene result in hemophilia A , an X-linked bleeding disorder .
The cost of Factor VIII and similar clotting factors has been described as "highly expensive". [21] The cost of the clotting factors is 80% of all medical costs for people with hemophilia. [ 23 ] They are so expensive that gene therapy for haemophilia might be less expensive, especially for people with severe hemophilia.
Marstacimab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people aged twelve years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Hemophilia A causes a deficiency in Factor VIII, a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [1] Contamination of these and other products caused large numbers of hemophiliacs to become infected with HIV and hepatitis C.
Diagnosis of haemophilia A also includes a severity level, which can range from mild to severe based on the amount of active and functioning factor VIII detected in the blood. Factor VIII levels do not typically change throughout an individual's lifetime. Severe haemophilia A is the most common severity, occurring in the majority of affected ...
Treatment and prevention of bleeding episodes is done primarily by replacing the missing blood clotting factors using "synthetic" or "non-human derived" factor products such as recombinant factor VIII. [24] Factor products work by replacing the missing factor proteins, which can take place at home or in hospital. In the 1970s, haemophiliacs ...
Ad
related to: factor viii warnings